STOCK TITAN

Wellgistics Health (WGRX) director exercises 100K-share warrant position

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Wellgistics Health director Surendra K. Ajjarapu exercised warrants to acquire 100,000 shares of Common Stock at $0.005 per share on June 22, 2026. The warrants had been issued on March 31, 2026 in lieu of cash compensation. Following the issuer’s reverse stock split effective May 26, 2026 and this warrant conversion, Ajjarapu directly holds 257,645 shares of Common Stock, and the exercised warrant position is reduced to zero.

Positive

  • None.

Negative

  • None.
Insider AJJARAPU SURENDRA K
Role null
Type Security Shares Price Value
X Warrant 100,000 $0.00 --
X Common Stock 100,000 $0.005 $500.00
Holdings After Transaction: Warrant — 0 shares (Direct, null); Common Stock — 257,645 shares (Direct, null)
Footnotes (1)
  1. Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person. Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants.
Shares acquired via exercise 100,000 shares Common Stock acquired on June 22, 2026 through warrant exercise
Exercise price $0.005 per share Conversion or exercise price for warrants into Common Stock
Post-transaction holdings 257,645 shares Common Stock directly held after reverse split and warrant conversion
Warrants exercised 100,000 warrants Derivative position in Warrants converted into Common Stock
Warrant expiration March 31, 2031 Original expiration date of exercised warrants
Exercise of in-the-money or at-the-money derivative security financial
"transaction_code_description: Exercise of in-the-money or at-the-money derivative security"
Warrants financial
"Represents the conversion of warrants (the "Warrants") issued to the Reporting Person"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
in lieu of cash compensation financial
"Warrants issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due"
reverse stock split financial
"Reflects the aggregate amount of Common Stock held following the Issuer's reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Common Stock financial
"Reflects the aggregate amount of Common Stock held by the Reporting Person"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
AJJARAPU SURENDRA K

(Last)(First)(Middle)
C/O WELLGISTICS HEALTH, INC.
3000 BAYPORT DRIVE, SUITE 950

(Street)
TAMPA, FLORIDA 33607

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Wellgistics Health, Inc. [ WGRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026X100,000(1)A$0.005257,645(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant$0.00506/22/2026X100,00003/31/202603/31/2031Common Stock100,000$00D
Explanation of Responses:
1. Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person.
2. Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants.
/s/ Surendra K Ajjarapu06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Wellgistics Health (WGRX) report in this Form 4?

Wellgistics Health reported that director Surendra K. Ajjarapu exercised warrants to acquire 100,000 shares of Common Stock at $0.005 per share. The transaction converted derivative warrants into direct share ownership without any reported open-market buying or selling activity.

How many Wellgistics Health (WGRX) shares does the director hold after the warrant exercise?

After the warrant exercise, Surendra K. Ajjarapu directly holds 257,645 shares of Wellgistics Health Common Stock. This figure reflects both the company’s reverse stock split effective May 26, 2026 and the shares issued from converting the warrants into Common Stock.

What were the key terms of the warrants exercised in the Wellgistics Health (WGRX) Form 4?

The warrants allowed acquisition of 100,000 shares of Wellgistics Health Common Stock at a conversion or exercise price of $0.005 per share. They were originally issued to Surendra K. Ajjarapu on March 31, 2026 in lieu of cash compensation owed to him.

Did the Wellgistics Health (WGRX) insider Form 4 report any open-market stock sales or purchases?

The Form 4 shows no open-market purchases or sales. Instead, it reports an in-the-money exercise of derivative warrants into 100,000 Common Stock shares, with the warrants going to zero and the director’s direct share holdings increasing accordingly.

How did Wellgistics Health’s (WGRX) reverse stock split affect the insider’s reported holdings?

The reported 257,645 Common Stock shares held by Surendra K. Ajjarapu already incorporate the effects of Wellgistics Health’s reverse stock split effective May 26, 2026, as well as the additional shares issued through the conversion of his warrants.